CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Mode of Death in Heart Failure With Preserved Ejection Fraction Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus Switching P2Y12-receptor inhibitors in patients with coronary artery disease

Review Article2017 Apr;110(4):259-272

JOURNAL: Article Link

Contemporary use of drug-coated balloons in coronary artery disease: Where are we now?

Picard F, Doucet S, Asgar AW Keywords: Angioplastie percutanée; Athérosclérose; Ballon médicamenté; Drug-coated balloon; Drug-eluting balloon; In-stent restenosis; Paclitaxel; Percutaneous coronary intervention; Resténose intra-stent

ABSTRACT

The drug-coated balloon (DCB) has emerged as an additional tool in the arsenal of interventional cardiology devices; it delivers antiproliferative drugs to local arterial tissue by single prolonged coated balloon angioplasty inflation, and prevents restenosis, leaving no implant behind. This strategy theoretically decreases the risk of late inflammatory response to device components, without preventing positive remodelling. DCBs, when used carefully and with a good technique, may have a role in the treatment of lesion subsets, such as in-stent restenosis, small vessel disease or side branch bifurcations, in which the implantation of a drug-eluting stent is not desirable or is technically challenging. Using the latest evidence regarding the effectiveness of the currently available DCBs, this review will discuss the rationale for DCB use, and the effectiveness of DCBs in different clinical and lesion settings, and will give practical tips for their correct use in everyday clinical practice.